Nanosonics (NAN) Stock Overview
Operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NAN passed our risk checks.
NAN Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
Nanosonics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.64 |
| 52 Week High | AU$5.18 |
| 52 Week Low | AU$2.88 |
| Beta | 1.79 |
| 1 Month Change | 14.00% |
| 3 Month Change | 21.15% |
| 1 Year Change | 31.82% |
| 3 Year Change | 29.61% |
| 5 Year Change | -15.33% |
| Change since IPO | 465.85% |
Recent News & Updates
With Nanosonics Limited (ASX:NAN) It Looks Like You'll Get What You Pay For
Oct 07
Nanosonics Limited's (ASX:NAN) Intrinsic Value Is Potentially 31% Above Its Share Price
Jul 04Recent updates
With Nanosonics Limited (ASX:NAN) It Looks Like You'll Get What You Pay For
Oct 07Nanosonics Limited's (ASX:NAN) Intrinsic Value Is Potentially 31% Above Its Share Price
Jul 04Nanosonics (ASX:NAN) Ticks All The Boxes When It Comes To Earnings Growth
Mar 30We Think Nanosonics' (ASX:NAN) Solid Earnings Are Understated
Feb 26Nanosonics Limited's (ASX:NAN) Shares Climb 26% But Its Business Is Yet to Catch Up
Feb 24
CORIS FDA Filing Will Set New Standard In Endoscopy Reprocessing
Strategic growth in high-margin recurring revenue and further North American market penetration in the trophon business suggest enhanced revenue and net margins.Nanosonics Limited (ASX:NAN) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jan 22Nanosonics (ASX:NAN) Is Reinvesting At Lower Rates Of Return
Nov 28Nanosonics Limited's (ASX:NAN) Shares Climb 29% But Its Business Is Yet to Catch Up
Sep 18Returns On Capital At Nanosonics (ASX:NAN) Paint A Concerning Picture
Feb 27Some Confidence Is Lacking In Nanosonics Limited (ASX:NAN) As Shares Slide 33%
Jan 24Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?
Nov 08Investors Will Want Nanosonics' (ASX:NAN) Growth In ROCE To Persist
Oct 04Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?
Jul 12Nanosonics (ASX:NAN) Will Be Hoping To Turn Its Returns On Capital Around
May 16Is Now The Time To Look At Buying Nanosonics Limited (ASX:NAN)?
Feb 09This Is Why Nanosonics Limited's (ASX:NAN) CEO Compensation Looks Appropriate
Nov 11A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)
Oct 28What Does Nanosonics Limited's (ASX:NAN) Share Price Indicate?
Oct 06A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)
Jul 18At AU$3.36, Is Nanosonics Limited (ASX:NAN) Worth Looking At Closely?
Jun 26Nanosonics (ASX:NAN) Will Want To Turn Around Its Return Trends
Jun 07A Look At The Intrinsic Value Of Nanosonics Limited (ASX:NAN)
Mar 08Nanosonics Limited (ASX:NAN) Analysts Just Cut Their EPS Forecasts
Feb 15Is Now The Time To Look At Buying Nanosonics Limited (ASX:NAN)?
Feb 02Nanosonics Limited's (ASX:NAN) CEO Looks Due For A Compensation Raise
Nov 12Returns Are Gaining Momentum At Nanosonics (ASX:NAN)
Aug 03An Intrinsic Calculation For Nanosonics Limited (ASX:NAN) Suggests It's 21% Undervalued
Mar 30Shareholder Returns
| NAN | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -0.2% | 1.9% | 1.2% |
| 1Y | 31.8% | 2.2% | 8.5% |
Return vs Industry: NAN exceeded the Australian Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: NAN exceeded the Australian Market which returned 8.5% over the past year.
Price Volatility
| NAN volatility | |
|---|---|
| NAN Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 10.5% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 20.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: NAN has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NAN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 470 | Michael Kavanagh | www.nanosonics.com.au |
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform.
Nanosonics Limited Fundamentals Summary
| NAN fundamental statistics | |
|---|---|
| Market cap | AU$1.41b |
| Earnings (TTM) | AU$20.68m |
| Revenue (TTM) | AU$198.63m |
Is NAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAN income statement (TTM) | |
|---|---|
| Revenue | AU$198.63m |
| Cost of Revenue | AU$43.27m |
| Gross Profit | AU$155.36m |
| Other Expenses | AU$134.68m |
| Earnings | AU$20.68m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 78.22% |
| Net Profit Margin | 10.41% |
| Debt/Equity Ratio | 0% |
How did NAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 20:42 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanosonics Limited is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Josh Kannourakis | Barrenjoey Markets Pty Limited |
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |